Columbus Health Products (CHP) GmbH

CHP GmbH is a medical technology company and medical product manufacturer based in Düsseldorf. It is involved in the research and development of innovative stimulation methods for the cellular control of inflammation and regeneration. The Axomera therapy developed by CHP is used by medical specialists in Europe for the conservative treatment of pain disorders, musculoskeletal disorders and in sports medicine. CHP cooperates with clinicians and researchers at the Universities of Aberdeen – Scotland (basic research) and Hannover, Tübingen, Greiswald to conduct clinical randomised multicentre trials.

Axomera is a brand of Columbus Health Products (CHP) GmbH.


Prof. Dr. med. Albrecht Molsberger, Specialist for Orthopaedics and Pain, Ruhr University Bochum and Private Clinic Düsseldorf – (CEO)

Dr. med. Gabriele Boewing, Specialist for Internal Medicine and Rheumatology, Düsseldorf – (CMO)

Philipp Schröder: doctor and entrepreneur, Düsseldorf – (CTO)


Kasernenstr 1b , 40213 Düsseldorf. Phone: +49 (0) 211 15806330. Fax: +49 (0) 211 15209962


HRB 32326; VAT ID DE187891014

© 2021 axomera – inspiring medicine. all rights reserved.
Axomera is a novel treatment method developed on the basis of established methods. Although studies have been carried out on Axomera, like the majority of established medical treatments, it has not yet been fully validated according to the principles of evidence-based medicine. In particular, no randomized controlled trials or comprehensive meta-analyses have yet been carried out. The success of Axomera therapy cannot be guaranteed in every case. However, there are a large number of patient reports, case studies and testimonials on conditions that have been successfully treated with Axomera therapy. They may be found on this website and also on

en_GBEnglish (UK)